Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates

Vaccine

Volumn 28, Issue 19, 2010, Pages 3453-3461

  Morera, Yanelys ^a   Bequet Romero, Mónica ^a   Ayala, Marta ^a   Velazco, Jorge Castro ^a   Pérez, Pedro Puente ^a   Alba, Jesús Suárez ^a   Ancizar, Julio ^a   Rodríguez, Meilyn ^a   Cosme, Karelia ^a   Gavilondo, Jorge V ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Cancer; Vaccine; VEGF

Indexed keywords

CANCER VACCINE; CIGB 247; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 51; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VERY SMALL SIZED PROTEOLIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL OUTER MEMBRANE; BEHAVIOR; BLOOD CHEMISTRY; CANCER IMMUNIZATION; CERCOPITHECUS; CONTROLLED STUDY; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGY; HISTOLOGY; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEOLIPOSOME; RABBIT; RAT; SKIN TEST; T LYMPHOCYTE; WOUND HEALING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; BACTERIAL OUTER MEMBRANE PROTEINS; CANCER VACCINES; CERCOPITHECINAE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; LIPOSOMES; MICE; NEISSERIA MENINGITIDIS; NEOPLASMS; OLEIC ACIDS; RABBITS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950628629     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.069     Document Type: Article

References (37)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6 April (4) (2007) 273-286
2. Humar R., Kiefer F.N., Berns H., Resink T.J., and Battegay E.J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16 June (8) (2002) 771-780
3. Ma L., del S.P., and Wallace J.L. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci USA 99 October (20) (2002) 13243-13247
4. Sleijfer S., Kruit W.H., and Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 40 November (16) (2004) 2377-2382
5. Ferrara N., Hillan K.J., and Novotny W. Bevacizumab (avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333 July (2) (2005) 328-335
6. Konner J., and Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 4 October (Suppl. 2) (2004) S81-5-S81-S85
7. Wachsberger P.R., Burd R., Cardi C., Thakur M., Daskalakis C., Holash J., et al. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol Phys 67 April (5) (2007) 1526-1537
8. Lu D., Jimenez X., Zhang H., Bohlen P., Witte L., and Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 97 January (3) (2002) 393-399
9. Hersey P., Bastholt L., Chiarion-Sileni V., Cinat G., Dummer R., Eggermont A.M., et al. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 20 August (Suppl. 6) (2009) vi35-40-vi35-vi40
10. Estevez F., Carr A., Solorzano L., Valiente O., Mesa C., Barroso O., et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 18 August (1-2) (1999) 190-197
11. Morera Y., Bequet-Romero M., Ayala M., Lamdan H., Agger E.M., Andersen P., et al. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 11 4 (2008) 381-393
12. Guthmann M.D., Bitton R.J., Carnero A.J., Gabri M.R., Cinat G., Koliren L., et al. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother 27 November (6) (2004) 442-451
13. Vanderlugt C.L., and Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2 February (2) (2002) 85-95
14. Morera Y., Lamdan H., Bequet M., Ayala M., Rojas G., Munoz Y., et al. Biologically active vascular endothelial growth factor as a bacterial recombinant glutathione S-transferase fusion protein. Biotechnol Appl Biochem 44 April (Pt 1) (2006) 45-53
15. Bequet-Romero M., Ayala M., Acevedo B.E., Rodriguez E.G., Ocejo O.L., Torrens I., et al. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis 10 1 (2007) 23-34
16. Perez L., Ayala M., Pimentel G., Bell H., Canaan-Haden L., Bequet M., et al. A multivalent recombinant antibody fragment specific for carcinoembryonic antigen. Biotechnol Appl Biochem 43 January (Pt 1) (2006) 39-48
17. Gonzalez G., Crombet T., Catala M., Mirabal V., Hernandez J.C., Gonzalez Y., et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 9 April (4) (1998) 431-435
18. Mesa C., de L.J., Rigley K., and Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 22 August (23-24) (2004) 3045-3052
19. Mesa C., de L.J., and Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 24 March (14) (2006) 2692-2699
20. Torrens I., Mendoza O., Batte A., Reyes O., Fernandez L.E., Mesa C., et al. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 23 December (50) (2005) 5768-5774
21. Ferreira I.A., Mocking A.I., Urbanus R.T., Varlack S., Wnuk M., and Akkerman J.W. Glucose uptake via glucose transporter 3 by human platelets is regulated by protein kinase B. J Biol Chem 280 September (38) (2005) 32625-32633
22. Walsh D.S., Gettayacamin M., Leitner W.W., Lyon J.A., Stewart V.A., Marit G., et al. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A. Vaccine 24 May (19) (2006) 4167-4178
23. Yamashita S., Hirano K., Kuwasako T., Janabi M., Toyama Y., Ishigami M., et al. Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem 299 May (1-2) (2007) 19-22
24. Wang X.Q., Duan X.M., Liu L.H., Fang Y.Q., and Tan Y. Carboxyfluorescein diacetate succinimidyl ester fluorescent dye for cell labeling. Acta Biochim Biophys Sin (Shanghai) 37 June (6) (2005) 379-385
25. Livingston P.G., Kurane I., and Ennis F.A. Use of Epstein-Barr virus-transformed, autologous B-lymphoblastoid cells as antigen-presenting cells for establishment and maintenance of dengue virus-specific, human cytotoxic T lymphocyte clones. J Virol Methods 67 August (1) (1997) 77-84
26. Godoy-Ramirez K., Makitalo B., Thorstensson R., Sandstrom E., Biberfeld G., and Gaines H. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A 68 December (2) (2005) 71-80
27. Berlanga J., Cibrian D., Guillen I., Freyre F., Alba J.S., Lopez-Saura P., et al. Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond) 109 July (1) (2005) 83-95
28. Rad F.H., Le Buanec H., Paturance S., Larcier P., Genne P., Ryffel B., et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 104 February (8) (2007) 2837-2842
29. Wei Y.Q., Huang M.J., Yang L., Zhao X., Tian L., Lu Y., et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 98 September (20) (2001) 11545-11550
30. Kamstock D., Elmslie R., Thamm D., and Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 56 August (8) (2007) 1299-1309
31. Gonzalez G., Crombet T., Neninger E., Viada C., and Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vac 3 January (1) (2007) 8-13
32. Senger D.R. Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell 21 February (3) (2010) 377-379
33. Eskens F.A., and Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer 42 December (18) (2006) 3127-3139
34. Korc M. Targeted therapeutics in pancreatic cancer: a ray of hope. Clin Cancer Res 11 January (1) (2005) 410-411
35. Zheng Y., Watanabe M., Kuraishi T., Hattori S., Kai C., and Shibuya M. Chimeric VEGF-ENZ7/PlGF specifically binding to VEGFR-2 accelerates skin wound healing via enhancement of neovascularization. Arterioscler Thromb Vasc Biol 27 March (3) (2007) 503-511
36. Lin Y.S., Nguyen C., Mendoza J.L., Escandon E., Fei D., Meng Y.G., et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288 January (1) (1999) 371-378
37. Verheul H.M., Lolkema M.P., Qian D.Z., Hilkes Y.H., Liapi E., Akkerman J.W., et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 13 September (18 Pt 1) (2007) 5341-5347